Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10726378 | 0.82 | MEN1 (0.43) | ATAD2 | |
| SCHEMBL376391 | 0.81 | ATAD2 (0.47) | ATAD2 | |
| SCHEMBL30847882 | 0.81 | ATAD2 (0.40) | ATAD2 | |
| SCHEMBL161148 | 0.80 | ATAD2 (0.54) | ATAD2ALDH1A1 | |
| SCHEMBL28636559 | 0.79 | DPYD (0.42) | — | |
| SCHEMBL28628364 | 0.78 | LMNA (0.39) | ATAD2 | |
| SCHEMBL30716110 | 0.77 | GAA (0.47) | ATAD2ALDH1A1 | |
| SCHEMBL17682900 | 0.76 | ATAD2 (0.42) | ATAD2 | |
| SCHEMBL5801041 | 0.76 | DPYD (0.59) | KDM4E | |
| SCHEMBL2028863 | 0.75 | KDM4E (0.48) | ATAD2KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| CN-106998692-B | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10577380-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2020-03-03 | — | — | US | disclosed |
| US-6339151-B1 | FORMING COMPOUNDS USING A NUCLEIC ACID BASE WITH A PHOSPHOROUS HALIDE TO FORM DRUGS FOR NONPROLIFERATION OF CELLS | NEWBIOTICS, INC. | 2002-01-15 | — | — | US | disclosed |
| EP-1167972-A2 | Enzyme catalyzed therapeutic agents | Newbiotics Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010034440-A1 | Enzyme catalyzed therapeutic agents | KIADIS PHARMA INTELLECTUAL PROPERTY B.V. (NL) | 2001-10-25 | — | — | US | disclosed |
| US-6245750-B1 | THYMIDINE PHOSPHORAMIDE DERIVATIVE; ANTIPROLIFERATIVE, ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS; | NEWBIOTICS, INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001007087-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007454-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007088-A2 | METHODS FOR TREATING THERAPY-RESISTANT TUMORS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1045897-A4 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS INC (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1045897-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | Newbiotics Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999037753-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577380-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | ATAD2 966/4885KDM4E 1468/4885ALDH1A1 4078/4885 |
| US-20010034440-A1 | Enzyme catalyzed therapeutic agents | DNPEP, AGBL2, ENTPD2 | ATAD2 2968/4885KDM4E 3064/4885ALDH1A1 2126/4885 |
| US-11584757-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | ATAD2 966/4885KDM4E 1468/4885ALDH1A1 4078/4885 |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | ATAD2 966/4885KDM4E 1468/4885ALDH1A1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.